A Phase 1/2, Randomized, Observer-blind, Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an hMPV/RSV mRNA Vaccine Candidate in Adult Participants Aged 60 Years and Older
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs SP 0256 (Primary)
- Indications Metapneumovirus infections; Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 22 Nov 2024 Status changed from not yet recruiting to recruiting.
- 20 Nov 2024 New trial record